Michel Vounatsos is on his way out as Bio­gen shut­ters Aduhelm ef­fort and launch­es pipeline re­org

Stymied by Medicare and forced to ad­mit the end of its once sky-high hopes in the con­tro­ver­sial Alzheimer’s med­i­cine Aduhelm, Bio­gen an­nounced this morn­ing that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER